Abstract
The activation mechanism of Carbonic Anhydrase was recently explained using kinetic, spectroscopic and X-ray techniques. It has been demonstrated that the activators molecules (CAAs) bind at the entrance of the enzyme active-site facilitating the ratedetermining step of CA catalitic cycle. Drug design studies have been performed in order to obtain strong CAAs belonging to several chemical classes: amino acids, azoles, amine and their derivatives, etc. Structure-activity correlations of different activators are discussed for the most studied Carbonic Anhydrase isozymes: isoform I and II. The physiological relevance of CA activation and the possible application of CAAs in Alzheimers desease and for other memory therapies are also treated.
Keywords: Carbonic anhydrase, X-ray structure, kinetic, enzyme activator, Alzheimer's desease
Current Pharmaceutical Design
Title: Carbonic Anhydrase Activation and the Drug Design
Volume: 14 Issue: 7
Author(s): Claudia Temperini, Andrea Scozzafava and Claudiu T. Supuran
Affiliation:
- Universita degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy.,Italy
Keywords: Carbonic anhydrase, X-ray structure, kinetic, enzyme activator, Alzheimer's desease
Abstract: The activation mechanism of Carbonic Anhydrase was recently explained using kinetic, spectroscopic and X-ray techniques. It has been demonstrated that the activators molecules (CAAs) bind at the entrance of the enzyme active-site facilitating the ratedetermining step of CA catalitic cycle. Drug design studies have been performed in order to obtain strong CAAs belonging to several chemical classes: amino acids, azoles, amine and their derivatives, etc. Structure-activity correlations of different activators are discussed for the most studied Carbonic Anhydrase isozymes: isoform I and II. The physiological relevance of CA activation and the possible application of CAAs in Alzheimers desease and for other memory therapies are also treated.
Export Options
About this article
Cite this article as:
Temperini Claudia, Scozzafava Andrea and Supuran T. Claudiu, Carbonic Anhydrase Activation and the Drug Design, Current Pharmaceutical Design 2008; 14(7) . https://dx.doi.org/10.2174/138161208783877857
| DOI https://dx.doi.org/10.2174/138161208783877857 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of 2, 4, 5-Triphenylimidazole Derivatives with Preliminary SAR
Letters in Drug Design & Discovery Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Impaired Cognitive Function is Associated with Motor Function and Activities of Daily Living in Mild to Moderate Alzheimer's Dementia
Current Alzheimer Research Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings
Current Psychopharmacology Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Naturally Arising CD25+CD4+ Regulatory T Cells in Maintaining Immunologic Self-Tolerance and Preventing Autoimmune Disease
Current Molecular Medicine State of the Evidence: Intimate Partner Violence and HIV/STI Risk Among Adolescents
Current HIV Research Prenatal Care for Women with Schizophrenia
Current Women`s Health Reviews Targeted Genome Editing Tools for Disease Modeling and Gene Therapy
Current Gene Therapy Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System
Current Neuropharmacology Use and Results of Antidepressant Treatment: Patients' Perception
Current Drug Therapy Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism Growth Hormone/Insulin-Like Growth Factor-I Axis and Insulin in Alzheimers Disease and Its Possible Treatment Usefulness
Central Nervous System Agents in Medicinal Chemistry A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Transgenic C. elegans as a Model in Alzheimers Research
Current Alzheimer Research




